
RCEL Stock Forecast & Price Target
RCEL Analyst Ratings
Bulls say
AVITA Medical's strong financial performance in the fourth quarter, with commercial revenue reaching $18.4 million and a year-over-year increase of 30%, highlights the company’s effective market penetration and product adoption for its RECELL system. The impressive gross profit margin of 87.6% reflects AVITA's pricing power and operational efficiency, positioning the company favorably within the acute wound care market. Looking forward, the combination of recent FDA approvals, expanded production capabilities, and strategic commercialization efforts suggests that AVITA is well-equipped to achieve accelerated revenue growth and capture more market share.
Bears say
Avita Medical's reliance on a single product, the RECELL system, may pose significant risks, particularly given its limited market penetration outside the US and a focus on burn centers, which could restrict growth potential. The decision to not actively market in established markets like Australia, Europe, Canada, and China further limits revenue diversification opportunities, placing heavy reliance on the US market's performance. Additionally, the adjustment of the price target from $25.00 to $22.00 indicates a cautious outlook reflecting potential concerns about future sales growth and market expansion.
This aggregate rating is based on analysts' research of AVITA Medical Inc and is not a guaranteed prediction by Public.com or investment advice.
RCEL Analyst Forecast & Price Prediction
Start investing in RCEL
Order type
Buy in
Order amount
Est. shares
0 shares